← All claims

Metabolic & Cardiometabolic

PCOS is a insulin resistance

Contested Metabolic & Cardiometabolic 🔬 Includes disconfirming

Part of: • PCOS

RefutedContestedStrong support
consensus score -0.15

📅 Last reviewed: 2026-07-15

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

2 support 4 contradict 0 tested null 3 mixed · 9 sources, 6 independent groups

What the evidence shows

PCOS is best understood as a primarily metabolic disorder (insulin resistance + cardiometabolic risk), not a purely reproductive/cosmetic one — the basis for the reclassification and the proposed rename to Polyendocrine Metabolic Ovarian Syndrome (PMOS).

The evidence (11)

SourceGradeStanceQualityFinding
dalamaga-2026
2026
observational supports low 56-org consortium reframes PCOS as metabolic (PMOS); editorial — emerging.
Chan JL et al
2026 · study_type: mechanism
observational mixed moderate Renames PCOS 'polyendocrine metabolic ovarian syndrome (PMOS)'; reviews pathophysiology as multisystem (endocrine+metabolic+reproductive), pathophysiology 'not entirely known.'
Kumar P et al
2026 · study_type: mechanism
mechanism contradicts moderate # was invalid enum "medium" (silently read as 1.0 anyway); normalized 2026-08-18 Hyperandrogenism, anovulation, and metabolic dysfunction 'traditionally assumed' as causative for subfertility, but paper argues microbiome/immune dysregulation add independent, non-metabolic causal pathways.
Moran LJ, Misso ML, Wild RA, Norman RJ
2010 · Hum Reprod Update
meta-analysis supports high Measured the PREVALENCE of IGT, DM2 and metabolic syndrome in PCOS vs controls: metabolic syndrome OR 2.88 (95% CI 2.40-3.45), BMI-matched subset OR 2.20 (1.36-3.56); DM2 OR 4.43 (4.06-4.82), BMI-matched subset OR 4.00 (1.97-8.10); IGT OR 2.48 (1.63-3.77), BMI-matched subset OR 2.54 (1.44-4.47). The BMI-matched figures come from per-outcome subsets whose own study counts are not stated in the abstract; 35 studies is the whole pool across all three outcomes. Scope limit that governs how far this row supports the claim: the paper did not measure insulin resistance (this claim's object) and made no comparison of the metabolic against the reproductive dimension, so it evidences elevated metabolic COMORBIDITY that survives BMI matching, not metabolic PRIMACY. Prevalence only - the authors state that no studies reported metabolic syndrome incidence.
El-Sehrawy AAMA et al
2026 · study_type: observational
observational supports moderate # was invalid enum "medium" (silently read as 1.0 anyway); normalized 2026-08-18 Review states IR 'serves as a central molecular driver of major metabolic and reproductive complications' including infertility, obesity, and CV risk, integrating inflammation/dysbiosis/oxidative stress around hyperinsulinemia/hyperandrogen
Nandagopal PB et al
2026 · study_type: observational
observational mixed low Narrative review: PCOS 'driven by hyperandrogenism and insulin resistance' jointly; lifestyle/dietary interventions target both metabolic and endocrine pathways together.
Persson S et al
2026 · study_type: observational
observational mixed high Swedish registry, 297,215 women: hyperandrogenic PCOS phenotype had far higher risk of hypertension/dyslipidemia than normoandrogenic; concludes PCOS is 'not only a reproductive disorder but also a significant cardiovascular risk factor.'
Jiang M et al
2026 · study_type: meta-analysis
meta-analysis contradicts high Meta-analysis, 533 non-obese PCOS vs 574 controls: no significant difference in serum vitamin D; authors conclude low vitamin D 'may be driven by obesity rather than PCOS pathogenesis.'
Wang S et al
2026 · study_type: observational
observational contradicts high GenomicSEM: only 16.7% of PCOS genetic variance shared with female metabolic-syndrome factor; 83.3% MetS-independent and 'retained stronger reproductive-endocrine features.'
tay-2024
2024
meta-analysis mixed low Elevated clinical CVD events in PCOS.
Ayonrinde OT et al
2026 · study_type: observational
observational contradicts moderate Longitudinal Raine Study (age 14→27): 'PCOS without MASLD or obesity in adolescence did not predict future insulin resistance' — only PCOS+MASLD conferred later IR/adverse cardiometabolic phenotype.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.